VISIONARY-MS Trial Reports CNM-Au8 Improves Vision and Cognition in Multiple Sclerosis
Newly announced data from the long-term extension (LTE) phase of the pivotal VISIONARY-MS trial (NCT03536559) showed that treatment with investigational CNM-Au8 (Clene Nanomedicine) resulted in improved progressive vision and cognition in patients with relapsing multiple sclerosis (MS). Full results of the LTE will be presented at the upcoming ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum.
Over 144 weeks of treatment, patients on CNM-Au8 demonstrated sustained improvements in low contrast vision, working memory, and information processing speed.
https://www.neurologylive.com/view/v...lerosis
Newly announced data from the long-term extension (LTE) phase of the pivotal VISIONARY-MS trial (NCT03536559) showed that treatment with investigational CNM-Au8 (Clene Nanomedicine) resulted in improved progressive vision and cognition in patients with relapsing multiple sclerosis (MS). Full results of the LTE will be presented at the upcoming ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum.
Over 144 weeks of treatment, patients on CNM-Au8 demonstrated sustained improvements in low contrast vision, working memory, and information processing speed.
https://www.neurologylive.com/view/v...lerosis